GSTM1 and NAT2 polymorphisms and colon, lung and bladder cancer risk: A case-control study

Anticancer Research

Volumn 29, Issue 5, 2009, Pages 1709-1714

  Zupa, Angela ^a   Sgambato, Alessandro ^a,b   Bianchino, Gabriella ^a,b   Improta, Giuseppina ^a   Grieco, Vitina ^a   La Torre, Giuseppe ^a   Campisi, Biagina ^a   Traficante, Antonio ^a   Aieta, Michele ^a   Cittadini, Achille ^a,b  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cancer susceptibility; Gene polymorphisms; Southern Italian region; Tumorigenesis

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENOMIC DNA; GLUTATHIONE TRANSFERASE M1;

ACETYLATOR PHENOTYPE; ARTICLE; BLADDER CANCER; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE ISOLATION; GENOTYPE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE;

AGED; ARYLAMINE N-ACETYLTRANSFERASE; BASE SEQUENCE; CASE-CONTROL STUDIES; COLONIC NEOPLASMS; DNA PRIMERS; FEMALE; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; URINARY BLADDER NEOPLASMS;

EID: 67650093556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nebert DW: Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 60: 265-271, 1997.
2. Wilson James F, Weale Michael E, Smith Alice C, Gratrix Fiona, Fletcher Benjamin, Thomas Mark G, Bradman Neil and Goldstein David B: Population genetic structure of variable drug response. Nature Genetics 29: 265-269, 2001. (Pubitemid 33096450)
3. Smith G, Stanley LA, Sim E, Strange RC and Wolf CR: Metabolic polymorphisms and cancer susceptibility. Cancer Surv 25: 27-65, 1995.
4. D'Errico A, Taglioli E, Chen X and Vineis P: Genetic Metabolic polymorphisms and the risk of cancer: a review of the literature. Biomarkers 1: 149-173, 1996. (Pubitemid 126710667)
5. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR and Peters U: Genetic susceptibility to cancer: the role of polymorphisms in candidate genes. JAMA 299: 2423-2436, 2008. (Pubitemid 351749241)
6. Rushmore TH and Pickett CB: Glutathione S-Transferases, structure, regulation and therapeutic implications. J Biol Chem 26: 11475-11478, 1993. (Pubitemid 23168082)
7. Seidegard J, Pero RW, Miller DG and Beattie EJ: A Glutathione S-Transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7: 751-753, 1986. (Pubitemid 17130636)
8. Seidegard J, Vorachek Wr, Pero RW and Pearson WR: Hereditary differences in the expression of the human glutathione transferase active on trans-stilibene oxide are due to a gene deletion. Proc. Natl. Acad Sci USA 8: 7293-7297, 1988.
9. Probst M, Blum M, Fasshaur i, D'Orazio D, Meyer U and Wild D: The role of the human acetylation polymorphism in the metabolic activation of the food carcinogen 2-amino-3-methylimidazol[4,5-f]quinoline (IQ). Carcinogenesis 13: 1713-1717, 1992.
10. Meyer UA and Zanger UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 37: 269-296, 1997. (Pubitemid 27238877)
11. Evans DA: N-acetyltransferase. Pharmacol Ther 42: 157-234, 1989.
12. Weber WW and Hein DW: N-acetylation pharmacogenetics. Pharmacol Rev 37: 25-79, 1985.
13. Hsieh FI, Pu YS, Chern HD, Hsu LI, Chiou HY and Chen CJ: Genetic polymorphisms of N-acetyltransferase 1 and 2 and risk of cigarette smoking-related bladder cancer. Br J Cancer 81: 537-541, 1999. (Pubitemid 29458811)
14. Yoshida K, Osawa K, Kasahara M, Miyaishi A, Nakanishi K, Hayamizu S, Osawa Y, Tsutou A, Tabuchi Y, Shimada E, Tanaka K, Yamamoto M and Takahashi J: Association of CYP1A1, CYP1A2, GSTM1 and NAT2 gene polymorphisms with colorectal cancer and smoking. Asian Pac J Cancer Prev 8: 438-444, 2007.
15. Kiss I, Németh A, Bogner B, Pajkos G, Orsós Z, Sándor J, Csejtey A, Faluhelyi Z, Rodler I and Ember I: Polymorphisms of glutathione-S-transferase and arylamine N-acetyltransferase enzymes and susceptibility to colorectal cancer. Anticancer Res 24: 3965-3970, 2004. (Pubitemid 40468694)
16. Okkels H, Sigsgaard T, Wolf H and Autrup H: Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol Biomarkers Prev 6: 225-231, 1997. (Pubitemid 27172886)
17. Lilla C, Verla-Tebit E, Risch A, Jäger B, Hoffmeister M, Brenner H and Chang-Claude J: Effect of NAT1 and NAT2 genetic polymorphisms on colorectal cancer risk associated with exposure to tobacco smoke and meat consumption. Cancer Epidemiol Biomarkers Prev 15: 99-107, 2006.
18. Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S, Tabuchi Y, Tsubota N and Takahashi J: NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 8: 103-108, 2007.
19. Miller SA, Dykes DD and Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16: 1215-1218, 1988.
20. Sgambato A, Campisi B, Zupa A, Bochicchio A, Romano G, Tartarone A, Galasso R, Traficante A and Cittadini A: Glutathione S-Trasferase (GST) polymorphism as risk factors for cancer in a highly homogeneous population from southern Italy. Anticancer Res 22: 3647-3652, 2002. (Pubitemid 36132844)
21. Bell DA, Taylor JA, Buttler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF and Lucier G: Genotype/Phenotype discordance for human arylamine N-Acetylyansferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis (Lond) 14: 189-192, 1993.
22. Perera FP: Molecular epidemiology: on the path to prevention. J Natl Cancer Inst 92: 602-612, 2000.
23. Raunio H, Husgafvel PK, Anttila S, Hietanen E, Hirvonen A and Pelkonen O: Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility - a review. Gene 159: 113-121, 1995.
24. Roots I, Drakoulis N and Brockmoller J: Polymorphic enzymes and cancer risk; concepts, methodology and data. Review in Pharmacogenetics of Drug Metabolism. Kalow W (ed.). Pergamon Press, New York, pp. 815-841, 1992.
25. Caporaso N, Landi MT and Vineis P: Relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1: 4-19, 1991.